We considered the implications of our findings of this adaptive Cav-1-mediated glycosphingolipid mechanism and developed the hypothesis that targeting of the ceramide to glycosphingolipid conversion may represent an actionable metabolic vulnerability in prostate cancer. Here, CAV1 is linked to prostate carcinoma.